Gene therapy for ocular neovascularization: a cure in sight.
Recent advances in the field of ocular gene transfer have led researchers pursuing treatment for age-related macular degeneration and diabetic retinopathy to turn to gene therapy for the answer. Viral vector-mediated delivery of both anti-angiogenic proteins and molecules that inhibit the eye's endogenous pro-angiogenic factors has successfully diminished the pathology of ocular diseases in rodent models. A gene-therapy solution to the debilitating blindness caused by ocular neovascularization may be on the horizon.
Reich
Samuel J
SJ
FM Kirby Center for Molecular Ophthalmology, Scheie Eye Institute, The University of Pennsylvania, 310 Stellar Chance Labs, 422 Curie Blvd, Philadelphia, Pennsylvania 19104-6069, USA. sreich@mail.med.upenn.edu
Bennett
Jean
J
D000256:Adenoviridae; D000818:Animals; D020256:Choroidal Neovascularization / Q000628:therapy*; D004195:Disease Models, Animal; D005136:Eye Proteins; D015316:Genetic Therapy; D005822:Genetic Vectors; D051379:Mice; D009414:Nerve Growth Factors; D011506:Proteins / Q000235:genetics / Q000378:metabolism; D016372:RNA, Antisense; D051381:Rats; D015843:Serpins / Q000235:genetics / Q000378:metabolism; D040281:Vascular Endothelial Growth Factor Receptor-1 / Q000235:genetics / Q000378:metabolism; D000099174:Pigment Epithelium-Derived Factor
D005136:Eye Proteins; D009414:Nerve Growth Factors; D011506:Proteins; D016372:RNA, Antisense; D015843:Serpins; D040281:Vascular Endothelial Growth Factor Receptor-1; D000099174:Pigment Epithelium-Derived Factor